MedTrace Logo

Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

NCT01139905 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-03-26

No results posted yet for this study

Summary

To study the pharmacokinetics of low-dose lopinavir/ritonavir tablet in HIV-1 infected Thai children.

Conditions

  • HIV-1 Infections

Interventions

OTHER

lopinavir/ritonavir

standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.

Sponsors & Collaborators

  • Chulalongkorn University

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Kiat Ruxrungtham, MD · The HIV Netherlands Australia Thailand Research Collaboration

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01139905 on ClinicalTrials.gov